This new weight loss drug ETF bets big on two of the industry's leading players
Publishing timestamp: 2024-05-27 12:01:01
Summary
Roundhill Investments has launched an ETF focused on GLP-1 weight loss drugs, betting on the long-term growth potential of the industry. The ETF includes leaders like Eli Lilly and Novo Nordisk, as well as other players developing new treatments. CEO Dave Mazza believes there is still plenty of room for growth in the weight loss drug market, comparing it to the trajectory of AI-linked stocks.
Sentiment: POSITIVE
Tickers: LLY, ZEAL-DK, NOVO.B-DK, NVDA, AMGN, 4519.T-JP,
Keywords: investment strategy, stock markets, biotech and pharmaceuticals, pharmaceuticals, eli lilly and co, markets, personal investing, breaking news: investing, business news, amgen inc, exchange-traded funds, zealand pharma a/s, novo nordisk a/s, nvidia corp, chugai pharmaceutical co ltd, roundhill glp-1 & weight loss etf,
Source: https://www.cnbc.com/2024/05/27/weight-loss-drug-etf-bets-big-on-eli-lilly-novo-nordisk.html